JP2021514193A5 - - Google Patents

Info

Publication number
JP2021514193A5
JP2021514193A5 JP2020544223A JP2020544223A JP2021514193A5 JP 2021514193 A5 JP2021514193 A5 JP 2021514193A5 JP 2020544223 A JP2020544223 A JP 2020544223A JP 2020544223 A JP2020544223 A JP 2020544223A JP 2021514193 A5 JP2021514193 A5 JP 2021514193A5
Authority
JP
Japan
Prior art keywords
sequence
bcma
lymphoma
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018698 external-priority patent/WO2019164891A1/en
Publication of JP2021514193A publication Critical patent/JP2021514193A/ja
Publication of JP2021514193A5 publication Critical patent/JP2021514193A5/ja
Pending legal-status Critical Current

Links

JP2020544223A 2018-02-21 2019-02-20 Bcma結合抗体及びその使用 Pending JP2021514193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633152P 2018-02-21 2018-02-21
US62/633,152 2018-02-21
PCT/US2019/018698 WO2019164891A1 (en) 2018-02-21 2019-02-20 Bcma-binding antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2021514193A JP2021514193A (ja) 2021-06-10
JP2021514193A5 true JP2021514193A5 (https=) 2023-08-29

Family

ID=65686040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544223A Pending JP2021514193A (ja) 2018-02-21 2019-02-20 Bcma結合抗体及びその使用

Country Status (15)

Country Link
US (2) US11401336B2 (https=)
EP (1) EP3755718A1 (https=)
JP (1) JP2021514193A (https=)
KR (1) KR20200123155A (https=)
CN (1) CN112272675A (https=)
AR (1) AR115257A1 (https=)
AU (1) AU2019223076A1 (https=)
BR (1) BR112020017053A2 (https=)
CA (1) CA3092037A1 (https=)
EA (1) EA202091974A1 (https=)
IL (1) IL276548A (https=)
MX (1) MX2020008718A (https=)
SG (1) SG11202007495SA (https=)
TW (1) TW202000701A (https=)
WO (1) WO2019164891A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099944A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CN115803027A (zh) * 2020-04-30 2023-03-14 百时美施贵宝公司 治疗细胞因子相关的不良事件的方法
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
US20250276092A1 (en) * 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
AU5305796A (en) 1995-03-10 1996-10-02 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101502T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
CN1342146A (zh) 1999-03-18 2002-03-27 塞尔基因公司 取代的1-氧代-和1,3-二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
NZ555886A (en) 2004-12-01 2009-12-24 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
EP1848433A2 (en) 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
CA2734330A1 (en) * 2008-09-19 2010-03-25 Medimmune, Llc Antibodies against sonic hedgehog homolog and uses thereof
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)­결합 단백질
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
KR102526945B1 (ko) * 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Cd269에 대한 인간화 항체
BR112017001183A2 (pt) * 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HRP20191873T1 (hr) * 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
TWI795133B (zh) * 2016-04-01 2023-03-01 美商凱特製藥公司 Bcma結合分子類及彼等之用途
KR20250175345A (ko) * 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체

Similar Documents

Publication Publication Date Title
JP2021514193A5 (https=)
JP2021506244A5 (https=)
JP2022506598A5 (https=)
JP2021501605A5 (https=)
CN117959417A (zh) 嵌合抗原受体和pd-1抑制剂的组合疗法
JP2020501531A5 (https=)
KR20190020297A (ko) 항-gitr 항체 및 그것의 사용
JP2023015171A (ja) 癌の組合せ治療
JP7584453B2 (ja) Taciを標的とする抗体及びキメラ抗原受容体
CN110461363B (zh) 靶向cd37的嵌合抗原受体
EP3830122A1 (en) Dosing regimen for bcma-cd3 bispecific antibodies
CN112292399A (zh) 抗cd27抗体及其用途
TW202221035A (zh) 抗ilt2抗體及其用途
JP2026032195A (ja) 関節リウマチのための皮下トシリズマブの改良された投薬量
JP2025170264A (ja) 抗bcma剤のための投与レジメン
CN118557697A (zh) 用于癌症的组合治疗
WO2018225033A1 (en) Combination therapy
US20250136704A1 (en) Methods for administering a bcmaxcd3 binding molecule
Feng et al. Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
CN116199778A (zh) 抗4-1bb抗体及其用途
CN110709423A (zh) 用icos激动剂和ox40激动剂治疗癌症的组合疗法
US20230167188A1 (en) Anti-tumor necrosis factor receptor (tnfr2) antibodies and uses thereof
WO2023208990A1 (en) Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
US20200190195A1 (en) Combination therapy with icos agonist and ox40 agonist to treat cancer
JC Exploring Novel Therapies for Idiopathic Inflammatory Myopathies and Examining Future Perspectives